Published in Am J Hematol on April 01, 2008
Gamma-delta T-cell lymphomas. Nat Rev Clin Oncol (2009) 1.28
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk (2012) 0.86
Epstein Barr Virus-positive large T-cell lymphoma presenting as acute appendicitis 17 years after cadaveric renal transplant: a case report. J Med Case Rep (2011) 0.82
Monitoring and safety of azathioprine therapy in inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr (2013) 0.81
Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant. Pediatr Blood Cancer (2009) 0.78
The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. Indian J Hematol Blood Transfus (2011) 0.77
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol (2009) 3.14
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol (2011) 2.87
The effect of obesity on renal transplant outcomes. Transplantation (2002) 2.29
Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients? Transplantation (2002) 1.98
Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. Clin Chem Lab Med (2015) 1.98
Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis (2008) 1.69
Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases. Nephrol Dial Transplant (2009) 1.68
Home haemodialysis in Australia - is the wheel turning full circle? Med J Aust (2010) 1.67
The honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. Perit Dial Int (2009) 1.66
Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis (2009) 1.61
Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with peritoneal dialysis. Perit Dial Int (2007) 1.59
The effect of oral iron admiinistration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. Transplantation (2004) 1.52
Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int (2009) 1.49
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant (2013) 1.47
Twenty-year remission of rheumatoid arthritis in 2 patients after allogeneic bone marrow transplant. J Rheumatol (2006) 1.45
Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int (2010) 1.45
Home hemodialysis and mortality risk in Australian and New Zealand populations. Am J Kidney Dis (2011) 1.37
A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol (2013) 1.36
Patients' priorities for health research: focus group study of patients with chronic kidney disease. Nephrol Dial Transplant (2008) 1.35
Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases. Clin J Am Soc Nephrol (2009) 1.31
Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases. Am J Kidney Dis (2010) 1.31
Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) (2007) 1.28
The impact of automated eGFR reporting and education on nephrology service referrals. Nephrol Dial Transplant (2008) 1.27
Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int (2003) 1.26
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adv Drug Deliv Rev (2004) 1.26
Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases. Nephrol Dial Transplant (2010) 1.24
Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant (2010) 1.24
Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis. Kidney Int (2010) 1.22
Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol (2011) 1.16
Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. BMC Nephrol (2009) 1.16
Polymicrobial peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes. Am J Kidney Dis (2009) 1.15
Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol (2012) 1.10
Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. Nephrol Dial Transplant (2009) 1.09
The impact of extended-hours home hemodialysis and buttonhole cannulation technique on hospitalization rates for septic events related to dialysis access. Hemodial Int (2010) 1.07
Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am J Kidney Dis (2003) 1.06
The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. BMC Nephrol (2012) 1.02
How Australian nephrologists view home dialysis: results of a national survey. Nephrology (Carlton) (2011) 1.02
Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients. Carcinogenesis (2004) 1.01
Association of dialysis modality and cardiovascular mortality in incident dialysis patients. Clin J Am Soc Nephrol (2009) 1.01
Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant (2005) 0.98
Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study. Am J Kidney Dis (2011) 0.94
Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol (2005) 0.94
Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney Int (2012) 0.93
Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients? Transplantation (2005) 0.92
Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants. Transplantation (2003) 0.92
Recovery of renal function in end-stage renal failure--comparison between peritoneal dialysis and haemodialysis. Nephrol Dial Transplant (2009) 0.92
A comparison of peritoneal equilibration tests performed 1 and 4 weeks after PD commencement. Perit Dial Int (2004) 0.91
Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrol Dial Transplant (2005) 0.91
Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol (2003) 0.91
Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. Nephrol Dial Transplant (2011) 0.90
Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nat Rev Nephrol (2011) 0.90
A randomized controlled trial of coiled versus straight swan-neck Tenckhoff catheters in peritoneal dialysis patients. Am J Kidney Dis (2006) 0.90
Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. Nephrol Dial Transplant (2011) 0.88
The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a randomised controlled trial. BMC Nephrol (2009) 0.87
End-stage kidney disease due to scleroderma--outcomes in 127 consecutive ANZDATA registry cases. Nephrol Dial Transplant (2011) 0.87
Quality of life and alternate nightly nocturnal home hemodialysis. Hemodial Int (2010) 0.87
Buttonhole cannulation and clinical outcomes in a home hemodialysis cohort and systematic review. Clin J Am Soc Nephrol (2013) 0.86
Cardiorespiratory fitness is independently associated with 25-hydroxyvitamin D in chronic kidney disease. Clin J Am Soc Nephrol (2010) 0.86
Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol (2011) 0.86
Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomes. Clin J Am Soc Nephrol (2013) 0.85
Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol (2005) 0.85
Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications. Adv Drug Deliv Rev (2006) 0.85
Daily variation in death in patients treated by long-term dialysis: comparison of in-center hemodialysis to peritoneal and home hemodialysis. Am J Kidney Dis (2012) 0.85
Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology (2002) 0.84
Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. Transplantation (2009) 0.84
A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients--the HEALTHY-CATH trial. BMC Nephrol (2012) 0.84
A randomized trial of sodium-restriction on kidney function, fluid volume and adipokines in CKD patients. BMC Nephrol (2014) 0.84
Prevention of access-related infection in dialysis. Expert Rev Anti Infect Ther (2009) 0.84
The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New Zealand. Clin J Am Soc Nephrol (2013) 0.84
End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrol Dial Transplant (2012) 0.84
Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. BMC Nephrol (2014) 0.84
Impact of obesity on renal transplant outcomes. Nephrology (Carlton) (2005) 0.84
Biocompatible peritoneal dialysis fluids: clinical outcomes. Int J Nephrol (2012) 0.83
Free fatty acids are associated with obesity, insulin resistance, and atherosclerosis in renal transplant recipients. Transplantation (2005) 0.83
Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients. NDT Plus (2009) 0.83
Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. Nephrology (Carlton) (2007) 0.83
Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD? Nephrology (Carlton) (2011) 0.83
Uremic toxin development in living kidney donors: a longitudinal study. Transplantation (2014) 0.82
A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients. Am J Kidney Dis (2006) 0.82
Home hemodialysis in Australia and New Zealand: how and why it has been successful. Semin Dial (2011) 0.82
Estimated GFR reporting influences recommendations for dialysis initiation. J Am Soc Nephrol (2013) 0.82
Australian consumer perspectives on dialysis: first national census. Nephrology (Carlton) (2012) 0.82
The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial. BMC Nephrol (2012) 0.81
A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. Br J Haematol (2008) 0.81
Effects of climatic region on peritonitis risk, microbiology, treatment, and outcomes: a multicenter registry study. Perit Dial Int (2012) 0.81
Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation. BJU Int (2008) 0.81
Change in live donor characteristics over the last 25 years: a single centre experience. Nephrology (Carlton) (2008) 0.81
Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: an interventional cohort study. BMC Nephrol (2011) 0.81
Review Article: is it time to embrace haemodiafiltration for centre-based haemodialysis? Nephrology (Carlton) (2008) 0.81
Outcomes of extended-hours hemodialysis performed predominantly at home. Am J Kidney Dis (2012) 0.81
A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. Br J Haematol (2012) 0.80
End-stage kidney disease due to haemolytic uraemic syndrome--outcomes in 241 consecutive ANZDATA registry cases. BMC Nephrol (2012) 0.80
Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. Transpl Int (2012) 0.80
Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology (Carlton) (2012) 0.80
High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease. Am J Blood Res (2012) 0.79
Relapsed plasma cell leukaemia presenting with aggressive extramedullary plasmacytomas in the meninges and testis--a missed opportunity for induction CNS prophylaxis. Leuk Lymphoma (2002) 0.79
Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant (2012) 0.79